Inosine-5’-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016)

References

• Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109:2903–2928.
   PubMed Web of Science ®Google Scholar
• Pimkin M, Markham GD. Inosine 5’-monophosphate dehydrogenase. Adv Enzymol Relat Areas Mol Biol. 2009;76:1–53.
   PubMedGoogle Scholar
• Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology. 2000;47:215–245.
   PubMed Web of Science ®Google Scholar
• Zhou S, Liu R, Baroudy BM, et al. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology. 2003;310:333–342.
   PubMed Web of Science ®Google Scholar
• Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999;6:575–597.
   PubMed Web of Science ®Google Scholar
• Deming P, Arora S. Taribavirin in the treatment of hepatitis C. Expert Opin Investig Drugs. 2011;20:1435–1443.
   PubMed Web of Science ®Google Scholar
• Grifantini M. Tiazofurine ICN Pharmaceuticals, Curr Opin Invest Drugs. 2000;1:257–262.
   PubMedGoogle Scholar
• Chen L, Pankiewicz KW. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel. 2007;10:403–412.
   PubMedGoogle Scholar
• Petrelli R, Vita P, Torquati I, et al. Novel inhibitors of inosine monophosphate dehydrogenase in patent literature of the last decade. Recent Pat Anticancer Drug Discov. 2013;8:103–125.
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US6344465B1. 2002.
   Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US5807876A. 1998.
   Google Scholar
• Vertex Pharmaceuticals to focus 2006 clinical development on therapies for hepatitis C virus infection, inflammation and cystic fibrosis. Available at: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=233059 [ cited 2016 Dec 1].
   Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US6541496B1. 2003.
   Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US6967214B2. 2005.
   Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US7329681B2. 2008.
   Google Scholar
• Markland W, McQuaid TJ, Jain J, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. 2000;44:859–866.
   PubMed Web of Science ®Google Scholar
• Sintchak MD, Fleming MA, Futer O, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell. 1996;85:921–930.
   PubMed Web of Science ®Google Scholar
• Sintchak MD, Nimmesgarn E. The structure of inosine 5ʹ-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology. 2000;47:163–184.
   PubMed Web of Science ®Google Scholar
• Li R-J, Wang Y-L, Wang Q-H, et al. In silico design of human IMPDH inhibitors using pharmacophore mapping and molecular docking approaches. Comput Math Methods Med. 2015; 2015:418767–418777.
   Web of Science ®Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US6498178B2. 2002.
   Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US7432290B2. 2008.
   Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US8268873B2. 2012.
   Google Scholar
• Hamilton JM, Harding MW, Genna T, et al. A phase I dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers. J Clin Pharmacol. 2009;49:30–38.
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals licenses vx-944 to Avalon Pharmaceuticals for development and commercialization in the treatment of cancer. Available at: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=233075 [ cited 2016 Dec 1].
   Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US7087642B2. 2006.
   Google Scholar
• Wallace EM, Moliterni JA, Moskal MA, et al. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme. J Med Chem. 1998;41:1513–1523.
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals Inc. Form 8-K, United States Securities and Exchange Commission, Washington, D.C., November 10, 2003 http://apps.shareholder.com/sec/viewerContent.aspx?companyid=VRTX&docid=2579491 [ cited 2016 Dec 1].
   Google Scholar
• Vertex Pharmaceuticals, Inc. Prodrugs of carbamate inhibitors of IMPDH. US6395763B1. 2002.
   Google Scholar
• Vertex Pharmaceuticals, Inc. Prodrugs of carbamate inhibitors of IMPDH. US6825224B2. 2004.
   Google Scholar
• Vertex Pharmaceuticals, Inc. Prodrugs of carbamate inhibitors of IMPDH. US7777069B2. 2010.
   Google Scholar
• Bristol-Myers Squibb Co. Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme. US6399773B1. 2002.
   Google Scholar
• Dhar TGM, Liu C, Pitts WJ, et al. A survey of cyclic replacements for the central diamide moiety of inhibitors of inosine monophosphate dehydrogenase. Bioorg Med Chem Lett. 2002;12:3125–3128.
   PubMed Web of Science ®Google Scholar
• Dhar TGM, Shen Z, Guo J, et al. Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]-amino]-5 oxazolyl]phenyl]-N-methyl-4-morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity. J Med Chem. 2002;45:2127–2130.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co. Compounds derived from an amine nucleus and pharmaceutical compositions comprising same. US6596747B2. 2003.
   Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of IMPDH enzyme. US6518291B1. 2003.
   Google Scholar
• Bristol-Myers Squibb Co. Inhibitors of IMPDH enzyme. US6420403B1. 2002.
   Google Scholar
• Bristol-Myers Squibb Co. Amino-substituted compounds useful as inhibitors of IMPDH enzyme. US6617323B2. 2003.
   Google Scholar
• Celltech R&D Ltd. Guanidine derivatives. WO2003045901A2. 2003.
   Google Scholar
• Bristol-Myers Squibb Co. Amide and diamide inhibitors of IMPDH enzyme for use in treating IMPDH-associated disorders. US6624184B1. 2003.
   Google Scholar
• Bristol-Myers Squibb Co. Inhibitors of IMPDH enzyme. US7053111B2. 2006.
   Google Scholar
• Bristol-Myers Squibb Co. Inhibitors of IMPDH enzyme. US7060720B2. 2006.
   Google Scholar
• Bristol-Myers Squibb Co. Inhibitors of IMPDH enzyme. US7205324B2. 2007.
   Google Scholar
• Gu HH, Iwanowicz EJ, Guo J, et al. Novel diamide-based inhibitors of IMPDH. Bioorg Med Chem Lett. 2002;12:1323–1326.
   PubMed Web of Science ®Google Scholar
• Watterson SH, Liu C, Dhar TGM, et al. Novel amide-based inhibitors of inosine 5ʹ-monophosphate dehydrogenase. Bioorg Med Chem Lett. 2002;12:2879–2882.
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors. US6867299B2. 2005.
   Google Scholar
• Vertex Pharmaceuticals Inc. Inhibitors of IMPDH enzyme technical field of the invention. US6653309B1. 2003.
   Google Scholar
• Vertex Pharmaceuticals Inc. Inhibitors of IMPDH enzyme technical field of the invention. US7989498B2. 2011.
   Google Scholar
• Bristol-Myers Squibb Co. Heterocycles that are inhibitors of IMPDH enzyme. US6919335B2. 2005.
   Google Scholar
• Watterson SH, Carlsen M, Dhar TGM, et al. Novel inhibitors of IMPDH: a highly potent and selective quinolone-based series. Bioorg Med Chem Lett. 2003;13:543–546.
   PubMed Web of Science ®Google Scholar
• Dhar TGM, Watterson SH, Chen P, et al. Quinolone-based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues. Bioorg Med Chem Lett. 2003;13:547–551.
   PubMed Web of Science ®Google Scholar
• Celltech R&D Ltd. Quinolone derivatives. US20030105073A1. 2003.
   Google Scholar
• Bristol-Myers Squibb Co. Heterocyclic acridone inhibitors of IMPDH enzyme. US6919335B2. 2005.
   Google Scholar
• Watterson SH, Chen P, Zhao Y, et al. Acridone-based inhibitors of inosine 5′-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419). J Med Chem. 2007;50:3730–3742.
   PubMed Web of Science ®Google Scholar
• Celltech R&D Ltd. Quinazolinone derivatives. WO2004022554A1. 2004.
   Google Scholar
• Birch HL, Buckley GM, Davies N, et al. Novel 7-methoxy-6-oxazol-5-yl-2,3-dihydro-1H-quinazolin-4-ones as IMPDH inhibitors. Bioorg Med Chem Lett. 2005;15:5335–5339.
   PubMed Web of Science ®Google Scholar
• Celltech R&D Ltd. Quinazolinedione derivatives. WO2003053958A1. 2005.
   Google Scholar
• Buckley GM, Davies N, Dyke HJ, et al. Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure–activity relationships. Bioorg Med Chem Lett. 2005;15:751–754.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co. 2-Substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same. US7008958B2. 2006.
   Google Scholar
• Institute of Medicinal Biotechnology, Chinese Academy Of Medical Sciences. Phenyl-oxazolyl derivatives, preparation method thereof, and related application of the phenyl-oxazolyl derivatives as an IMPDH inhibitor. WO2013131409A1. 2013.
   Google Scholar
• Gilead Sciences Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds. WO2004096287A2. 2004.
   Google Scholar
• Gilead Sciences Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds. US7427636B2. 2008.
   Google Scholar
• Pankiewicz KW, Petrelli R, Singh R, et al. Nicotinamide adenine dinucleotide based therapeutics, update. Curr Med Chem. 2015;22:3991–4028.
   PubMed Web of Science ®Google Scholar
• Chen L, Gao G, Felczak K, et al. Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues. J Med Chem. 2007;50:5743–5751.
   PubMed Web of Science ®Google Scholar
• Felczak K, Chen L, Wilson D, et al. Cofactor-type inhibitors of inosine monophosphate dehydrogenase via modular approach: targeting the pyrophosphate binding sub-domain. Bioorg Med Chem. 2011;19:1594–1605.
   PubMed Web of Science ®Google Scholar
• Chen L, Petrelli R, Olesiak M, et al. Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem. 2008;16:7462–7469.
   PubMed Web of Science ®Google Scholar
• Felczak K, Vince R, Pankiewicz KW. NAD-based inhibitors with anticancer potential. Bioorg Med Chem Lett. 2014;24:332–336.
   PubMed Web of Science ®Google Scholar
• Biota Inc. Nucleoside 5ʹ-monophosphate mimics and their prodrugs.  US20040023901A1. 2004.
   Google Scholar
• Chen L, Gao G, Bonnac L, et al. Methylenebis(sulfonamide) linked nicotinamide adenine dinucleotide analogue as an inosine monophosphate dehydrogenase inhibitor. Bioorg Med Chem Lett. 2007;17:3152–3155.
   PubMed Web of Science ®Google Scholar
• Nair V, Uchil V, Ma X, et al. Ribonucleosides bearing Michael acceptors: synthesis, molecular docking, enzyme inhibition data and antiviral activity. Nucleic Acids Symp Ser. 2008;52:625–626.
   Google Scholar
• Pal S, Bera B, Nair V. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by the antiviral compound, 2-vinylinosine monophosphate. Bioorg. Med Chem. 2002;10:3615–3618.
   PubMed Web of Science ®Google Scholar
• Nair V, Kamboj RC. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by 2-[2-(Z)-fluorovinyl]inosine 5′-monophosphate. Bioorg Med Chem Lett. 2003;13(4):645–647.
   PubMed Web of Science ®Google Scholar
• Nair V, Zhang F, Ma X, et al. Base-functionalized carbocyclic nucleosides: design, synthesis, and mechanism of antiviral activity. Nucleosides, Nucleotides Nucleic Acids. 2009;28:408–423.
   PubMed Web of Science ®Google Scholar
• Pickett SD, Sherborne BS, Wilkinson T, et al. Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorg Med Chem Lett. 2003;13:1691–1694.
   PubMed Web of Science ®Google Scholar
• Beevers RE, Buckley GM, Davies N, et al. Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006;16:2535–2538.
   PubMed Web of Science ®Google Scholar
• Beevers RE, Buckley GM, Davies N, et al. Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure–activity relationships. Bioorg Med Chem Lett. 2006;16:2539–2542.
   PubMed Web of Science ®Google Scholar
• Regents of The University of Minnesota Anticancer agents. WO2009018344A1. 2009.
   Google Scholar
• Striepen B, Pruijssers AJ, Huang J, et al. Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc. Natl. Acad. Sci. U. S. A.. 2004;101:3154−3159.
   PubMed Web of Science ®Google Scholar
• Umejiego NN, Gollapalli D, Sharling L, et al. Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis. Chem Biol. 2008;15:70–77.
   PubMed Web of Science ®Google Scholar
• Brandeis University and University of Georgia Research Foundation, Inc. Compounds and methods for treating mammalian gastrointestinal parasitic infections. US20100022547A1. 2010.
   Google Scholar
• Brandeis University and University of Georgia Research Foundation, Inc. Compounds and methods for treating mammalian gastrointestinal parasitic infections. US20120264760A1. 2012.
   Google Scholar
• Maurya SK, Gollapalli DR, Kirubakaran S, et al. Triazole inhibitors of Cryptosporidium parvum inosine 5ʹ-monophosphate dehydrogenase. J Med Chem. 2009;52:4623–4630.
   PubMed Web of Science ®Google Scholar
• MacPherson IS, Kirubakaran S, Gorla SK, et al. The structural basis of Cryptosporidium-specific IMP dehydrogenase inhibitor selectivity. J Am Chem Soc. 2010;132:1230–1231.
   PubMed Web of Science ®Google Scholar
• Kirubakaran S, Gorla SK, Sharling L, et al. Structure–activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. Bioorg Med Chem Lett. 2012;22:1985–1988.
   PubMed Web of Science ®Google Scholar
• Gorla SK, Kavitha M, Zhang M, et al. Selective and potent urea inhibitors of Cryptosporidium parvum inosine monophosphate dehydrogenase. J Med Chem. 2012;55:7759–7771.
   PubMed Web of Science ®Google Scholar
• Johnson CR, Gorla SK, Kavitha M, et al. Phthalazinone inhibitors of inosine-5ʹ-monophosphate dehydrogenase from Cryptosporidium parvum. Bioorg Med Chem Lett. 2013;23:1004–1007.
   PubMed Web of Science ®Google Scholar
• Gorla SK, Kavitha M, Zhang M, et al. Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum inosine 5′-mono phosphate dehydrogenase. J Med Chem. 2013;56:4028−4043.
   PubMed Web of Science ®Google Scholar
• Sun Z, Khan J, Makowska-Grzyska M, et al. Synthesis, in vitro evaluation and cocrystal structure of 4‑oxo- [1]benzopyrano[4,3‑c]pyrazole Cryptosporidium parvum inosine 5′-monophosphate dehydrogenase (CpIMPDH) inhibitors. J Med Chem. 2014;57:10544−10550.
   PubMed Web of Science ®Google Scholar
• Brandeis University, University of Georgia Research Foundation, Inc., and The Brigham and Women’s Hospital, Inc. Compounds and methods for treating mammalian gastrointestinal microbial infections.  US8969342B2. 2015.
   Google Scholar
• Brandeis University and The Brigham and Women’s Hospital, Inc. Compounds and methods for treating mammalian gastrointestinal microbial infections. US9447134B2. 2016.
   Google Scholar
• Gorla SK, McNair NN, Yang G, et al. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob Agents Chemother. 2014;58:1603−1614.
   PubMed Web of Science ®Google Scholar
• Mandapati K, Gorla SK, House AL, et al. Repurposing Cryptosporidium inosine 5′-monophosphate dehydrogenase inhibitors as potential antibacterial agents. ACS Med Chem Lett. 2014;5:846−850.
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals Inc. Inhibitors of bacterial IMPDH. US8202889B2. 2012.
   Google Scholar